Clinical Trials ·
This study evaluates the pharmacokinetics of Retatrutide in participants with renal impairment compared to healthy individuals. It aims to understand how the drug is absorbed into the bloodstream and eliminated from the body, which is crucial for determining appropriate dosing in patients with kidney issues.
What this source covers
The study registered under NCT05611957 focuses on assessing the pharmacokinetic properties of LY3437943, known as Retatrutide, in both healthy participants and those with impaired renal function. The trial will span up to five weeks, excluding the screening phase, and aims to elucidate how renal impairment affects the drug's absorption and elimination.
Why it matters for Retatrutide research
Understanding the pharmacokinetics of Retatrutide in individuals with renal impairment is essential for tailoring treatment regimens. As renal function can significantly impact drug metabolism and clearance, this study provides valuable insights that could influence clinical practices and dosing guidelines for patients with varying degrees of kidney function.
Key findings or claims
- The study assesses the pharmacokinetics of Retatrutide in healthy participants versus those with renal impairment.
- It aims to determine the amount of the drug that reaches systemic circulation.
- The trial duration is set for up to five weeks, excluding screening.
- The results will inform dosing considerations for patients with kidney issues.
- The study is critical for understanding the safety and efficacy of Retatrutide in diverse patient populations.
Context and prior work
Retatrutide is a dual agonist of GLP-1 and GIP receptors, which has shown promise in managing weight and improving metabolic health. Prior research has established the importance of understanding the pharmacological profiles of such agents, particularly in populations with comorbidities like renal impairment. This study adds to the body of literature that explores the pharmacokinetics of GLP-1 receptor agonists and their implications for clinical use.
Practical takeaways for researchers
This study highlights the necessity of conducting pharmacokinetic assessments in diverse patient populations, particularly those with renal impairment. Researchers should consider the implications of renal function on drug metabolism when designing clinical trials and interpreting results. Additionally, findings from this study may guide future research directions and clinical applications of Retatrutide.
FAQ
What is the main objective of the study?
The primary objective is to assess the pharmacokinetics of Retatrutide in participants with renal impairment compared to healthy individuals.
How long will the study last?
The study will last up to five weeks, excluding the screening period.
Why is this study important?
This study is important because it will provide insights into how renal impairment affects the pharmacokinetics of Retatrutide, which is crucial for safe and effective dosing in affected patients.
Source: ClinicalTrials.gov · NCT05611957 · published 2023-10-02.